Paper32101663
Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P and 21 others. N Engl J Med, 2020. Cited by 2,618 papers, by iCite.
Cite this record
ConductScience Library. Pembrolizumab for Early Triple-Negative Breast Cancer. Papers, record 32101663. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32101663
- Disease
- breast cancer1,032 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal, Humanized | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Triple Negative Breast Neoplasms | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Carboplatin | |
| Cyclophosphamide | |
| Doxorubicin | |
| Epirubicin | |
| Female | |
| Humans | |
| Intention to Treat Analysis | |
| Kaplan-Meier Estimate | |
| Middle Aged | |
| Neoadjuvant Therapy | |
| Neoplasm Staging | |
| Paclitaxel |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| N/A | Merck Sharp and Dohme | International | PubMed |
Source PubMed
Trials16
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT03036488 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT05132504 | Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer | Background | ClinicalTrials.gov | |
| NCT05213312 | Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC | Background | ClinicalTrials.gov | |
| NCT05275777 | A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer | Background | ClinicalTrials.gov | |
| NCT05763992 | Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial | Results | ClinicalTrials.gov | |
| NCT05843292 | Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer | Background | ClinicalTrials.gov | |
| NCT06225284 | Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients | Background | ClinicalTrials.gov | |
| NCT06245889 | PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC | Results | ClinicalTrials.gov | |
| NCT06497322 | Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment | Results | ClinicalTrials.gov | |
| NCT06610097 | TNBC Gut Microbiota During Neoadjuvant Treatment | Background | ClinicalTrials.gov | |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors | Background | ClinicalTrials.gov | |
| NCT07007169 | Mediterranean Diet and Inequality in Early Breast Cancer | Background | ClinicalTrials.gov | |
| NCT07188246 | Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer | Background | ClinicalTrials.gov | |
| NCT07394387 | Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer. | Background | ClinicalTrials.gov | |
| NCT07644455 | Percutaneous Biopsy After Neoadjuvant Chemotherapy. | Results | ClinicalTrials.gov | |
| NCT07743190 | A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs) | Background | ClinicalTrials.gov |
Comments and corrections5
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 32127649 | Moving pembrolizumab forwards. | https://conductscience.org/library/papers/32127649 | PubMed |
| Comment in | 32145769 | Pembrolizumab for triple-negative breast cancer. | https://conductscience.org/library/papers/32145769 | PubMed |
| Comment in | 32561940 | [Pembrolizumab as neoadjuvant treatment of early triple-negative breast cancer]. | https://conductscience.org/library/papers/32561940 | PubMed |
| Comment in | 32579834 | Pembrolizumab for Early Triple-Negative Breast Cancer. | https://conductscience.org/library/papers/32579834 | PubMed |
| Comment in | 36152640 | Toxicity and Timing of Breast Radiation Therapy With Overlapping Systemic Therapies. | https://conductscience.org/library/papers/36152640 | PubMed |
Cited by1,895
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2,618 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42983499 | T cell exhaustion in cancer: from functional decline to adaptive immune regulation. | Mol Cancer | 2026 | https://conductscience.org/library/papers/42983499 | PubMed |
| 42972023 | Early temporal transcriptional and cytokine responses distinguish chemotherapy sensitivity in patient-derived xenograft models of triple-negative breast cancer. | Oncogene | 2026 | https://conductscience.org/library/papers/42972023 | PubMed |
| 42967914 | Neoadjuvant concurrent or sequential anthracycline-containing chemotherapy and HER2-targeted agents for HER2-positive breast cancer: a randomized phase 2 study (METIS). | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42967914 | PubMed |
| 42964829 | Non-invasive electromagnetic fields induce anti-tumor neutrophil reprogramming and enhance checkpoint blockade in breast cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/42964829 | PubMed |
| 42957928 | Direct medical costs of breast cancer by subtype and stage in Korea: a patient-level retrospective cohort analysis. | Health Econ Rev | 2026 | https://conductscience.org/library/papers/42957928 | PubMed |
| 42948616 | Ductal Carcinoma In Situ With Microinvasion Arising in a Breast Hamartoma: A Case Report and Review of Guidelines of Hamartoma Management. | Case Rep Surg | 2026 | https://conductscience.org/library/papers/42948616 | PubMed |
| 42947999 | Dual PD-1/LAG-3 Blockade in Breast Cancer: Navigating Benefit and Risk. | Cancer Innov | 2026 | https://conductscience.org/library/papers/42947999 | PubMed |
| 42939797 | Subtype-Conditioned NRF2-KEAP1 Signaling in Breast Cancer: A Narrative Review and Hypothesis-Generating Framework from Chemoprevention to Therapy Resistance. | Antioxidants (Basel) | 2026 | https://conductscience.org/library/papers/42939797 | PubMed |
| 42938904 | Cancer Cell Metabolic Reprogramming: Dietary, Pharmacological Strategies and Clinical Perspectives. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42938904 | PubMed |
| 42938872 | Real-World Feasibility, Toxicity, and Early Outcomes of Neoadjuvant Pembrolizumab-Based Systemic Therapy in Early Triple-Negative Breast Cancer: A Single-Centre Chinese Cohort from Hong Kong. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42938872 | PubMed |
| 42938804 | MRI-Based Prediction of Immunotherapy Response in Breast Cancer: A Systematic Review. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42938804 | PubMed |
| 42936250 | Precision immuno-oncology in triple-negative breast cancer: from PD-L1 to multimodal biomarkers, ADC-ICI combinations, and global real-world integration. | Front Immunol | 2026 | https://conductscience.org/library/papers/42936250 | PubMed |
| 42931983 | Efficacy and toxicity for pembrolizumab-containing therapy in older adults with triple-negative breast cancer: insights from routine oncology practice. | Breast Cancer Res Treat | 2026 | https://conductscience.org/library/papers/42931983 | PubMed |
| 42931078 | Pesticide Exposure and Breast Cancer: Molecular Mechanisms, Epidemiological Evidence, and Current Challenges. | J Xenobiot | 2026 | https://conductscience.org/library/papers/42931078 | PubMed |
| 42930156 | Real-World Treatment Utilization and Patterns of Adjuvant Olaparib for Early-Stage Breast Cancer: Insights from the Komodo Research Database. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42930156 | PubMed |
| 42930141 | Cardiotoxicity of Immune Checkpoint Inhibitors with Anthracycline Chemotherapy in Triple-Negative Breast Cancer. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42930141 | PubMed |
| 42927318 | A HALF CENTURY OF PROGRESS IN BREAST CANCER: WHERE DO WE GO NEXT? | Trans Am Clin Climatol Assoc | 2026 | https://conductscience.org/library/papers/42927318 | PubMed |
| 42919392 | Unraveling the use of vaccine therapy in HER2-positive breast cancer: a comprehensive review of current state and future perspectives. | J Exp Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42919392 | PubMed |
| 42903114 | PD-1/PD-L1 inhibitors combined with chemotherapy or as monotherapy versus chemotherapy alone or observation in triple-negative breast cancer: a systematic review and updated meta-analysis incorporating long-term survival data. | Front Immunol | 2026 | https://conductscience.org/library/papers/42903114 | PubMed |
| 42886323 | Neoadjuvant Chemo-Immunotherapy Yields Survival Comparable to Upfront Surgery in Metaplastic Breast Cancer: A National Cancer Database Analysis. | Ann Surg Oncol | 2026 | https://conductscience.org/library/papers/42886323 | PubMed |
Drugs8
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL1200796 | ChEMBL |
| CARBOPLATIN | CHEMBL1351 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL1351 | ChEMBL |
| CAPECITABINE | CHEMBL1773 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1773 | ChEMBL |
| PEMBROLIZUMAB | CHEMBL3137343 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL3137343 | ChEMBL |
| EPIRUBICIN | CHEMBL417 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL417 | ChEMBL |
| PACLITAXEL | CHEMBL428647 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL428647 | ChEMBL |
| OLAPARIB | CHEMBL521686 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL521686 | ChEMBL |
| DOXORUBICIN | CHEMBL53463 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL53463 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32101663
GET https://conductscience.org/api/papers/v1/32101663/authors?page=2